Cystic fibrosis drug is not cost effective, says NICE

BMJ (Online)

Volumn 353, Issue , 2016, Pages

  Gulland, Anne ^a  

^a London   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IVACAFTOR PLUS LUMACAFTOR; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; IVACAFTOR; LUMACAFTOR; QUINOLONE DERIVATIVE; RESPIRATORY TRACT AGENT;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DRUG COST; DRUG EFFICACY; HUMAN; LUNG FUNCTION; NOTE; PRIORITY JOURNAL; COST BENEFIT ANALYSIS; ECONOMICS;

AMINOPHENOLS; AMINOPYRIDINES; BENZODIOXOLES; COST-BENEFIT ANALYSIS; CYSTIC FIBROSIS; HUMANS; QUINOLONES; RESPIRATORY SYSTEM AGENTS;

EID: 84975688066     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i3409     Document Type: Note

References (2)

1. National Institute for Health and Care Excellence. Final appraisal determination Lumacaftor-ivacaftor for treating cystic fibrosis homozygous for the F508del mutation. June 2016. www.nice.org.uk.
2. Konstan MW, McKone E, Moss RB, et al. Poster 108: evidence for reduced rate of lung function decline and sustained benefit with combination lumacaftor and ivacaftor (LUM/IVA) therapy in patients (pts) ≥12 years of age with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation. Presented at the 8th European Conference on Rare Diseases and Orphan Products (ECRD), Edinburgh, Scotland. 26-28 May 2016. www.rare-diseases.eu/wp-content/uploads/2013/08/FINAL-UVRTX3766-Konstan-105-ECRD-2016-052516d1-26May-7pm-2.pdf.